Skip to content

Ionis Pharmaceuticals Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 9, 2026 results vs estimates

Ionis Pharmaceuticals Inc · E.IONS.NASDAQ · United States
Use symbol E.IONS.NASDAQ in our API & Excel add-in to retrieve this data ↓
44.39
(-0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend -50%
Bubble Risk LOW
Realised Volatility (20D) 37.21%

Ionis Pharmaceuticals Inc Forecast

Ionis Pharmaceuticals Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is negative (2 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 37.2% a year, a typical one-standard-deviation range is 42.06–46.72 over a week, 39.62–49.16 over a month and 27.87–60.91 over a year. (Signals as of 1 Nov 2026.)

Ionis Pharmaceuticals Inc Price Chart

MacroFinance.ai

Ionis Pharmaceuticals Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Ionis Pharmaceuticals Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Ionis Pharmaceuticals Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Ionis Pharmaceuticals Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Ionis Pharmaceuticals Inc
P/S
7.69x
Mid-range vs own history
QoQ −32.0%
YoY −39.2%
now 7.68724.6 low14.38 high
ⓘP/S As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Ionis Pharmaceuticals Inc
P/B
18.74x
Mid-range vs own history
QoQ −16.6%
YoY −5.3%
now 18.742611.22 low27.44 high
ⓘP/B As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Ionis Pharmaceuticals Inc
EV/Sales
7.97x
Mid-range vs own history
QoQ −32.1%
YoY −32.9%
now 7.96734.88 low13.87 high
ⓘEV/Sales As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Ionis Pharmaceuticals Inc
FCF Yield
-8.4%
Mid-range vs own history
QoQ +47.7%
YoY +237.6%
now -8.3529-13.95 low-2.18 high
ⓘFCF Yield As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Ionis Pharmaceuticals Inc
Earnings Yield
-7.4%
Mid-range vs own history
QoQ +29.5%
YoY +253.2%
now -7.4025-12.36 low-1.84 high
ⓘEarnings Yield As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Ionis Pharmaceuticals Inc
Market Cap
$7.4B
Mid-range vs own history
QoQ −25.3%
YoY −39.7%
now 7377.83994,418 low13,906 high
ⓘMarket Cap As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Ionis Pharmaceuticals Inc
Net Debt
$269M
Mid-range vs own history
QoQ −26.1%
YoY −135.8%
now 268.861-750.51 low363.89 high
ⓘNet Debt As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Ionis Pharmaceuticals Inc
Current Ratio
5.43x
Mid-range vs own history
QoQ −31.2%
YoY +94.6%
now 5.42512.79 low7.88 high
ⓘCurrent Ratio As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Ionis Pharmaceuticals Inc
Quick Ratio
5.36x
Mid-range vs own history
QoQ −30.6%
YoY +93.0%
now 5.35942.78 low7.72 high
ⓘQuick Ratio As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Ionis Pharmaceuticals Inc
Interest Coverage
-6.51x
Weak vs own history
QoQ +16.1%
YoY +239.1%
now -6.5131-6.51 low-1.92 high
ⓘInterest Coverage As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Ionis Pharmaceuticals Inc
Debt / Equity
5.47x
Mid-range vs own history
QoQ −0.6%
YoY +126.9%
now 5.46892.41 low5.5 high
ⓘDebt / Equity As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Ionis Pharmaceuticals Inc
Piotroski F-Score
3
Mid-range vs own history
QoQ 0.0%
YoY −25.0%
now 33 low4 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Ionis Pharmaceuticals Inc
Altman Z-Score
0.902
Weak vs own history
QoQ −43.8%
YoY −66.6%
now 0.9020.2 low3.11 high
ⓘAltman Z-Score As of 22 Nov 2026.See Ionis Pharmaceuticals Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  20 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Ionis Pharmaceuticals Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Ionis Pharmaceuticals Inc fundamentals: income statement, balance sheet & cash flow

Ionis Pharmaceuticals Inc reported revenue of $944.0m and net income of -$381.0m in FY2025, the year ended 31 December 2025 — revenue up 33.9% and net income up 16.1% on the prior year. Free cash flow was -$320.0m. These figures are as reported in the filings, not restated: 36 fiscal years and 147 quarters of history, back to December 1990. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$944.0m
+33.9%
Net income
-$381.0m
+16.1%
Gross margin
98.31%
Free cash flow
-$320.0m
+41.4%
Net debt
$2.24bn
Shares short (30 Oct 2026)
21.17m
8.41 days to cover
Ionis Pharmaceuticals Inc income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue944.0705.1787.6587.4810.5
Cost of revenue16.011.29.114.110.8
Gross profit928.0693.9778.5573.3799.6
Research & development916.0901.5899.6833.0643.0
Selling, general & admin.393.9267.5232.6150.3—
Operating income-382.0-475.1-353.7-410.2-30.2
EBITDA-284.3-353.7-235.9-227.8-5.2
Interest expense90.590.581.58.19.3
Pre-tax income-380.0-460.1-334.0-258.0-29.1
Income tax1.0-6.232.311.7-0.6
Net income-381.0-453.9-366.3-269.7-28.6

Download Ionis Pharmaceuticals Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.IONS.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 36 fiscal years and 147 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Ionis Pharmaceuticals Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Ionis Pharmaceuticals Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Ionis Pharmaceuticals Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Ionis Pharmaceuticals Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Ionis Pharmaceuticals Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Ionis Pharmaceuticals Inc (United States)

Ionis Pharmaceuticals Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Ionis Pharmaceuticals Inc?
Ionis Pharmaceuticals Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Ionis Pharmaceuticals Inc price?
The latest close is 44.39 (1 Nov 2026), -0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Ionis Pharmaceuticals Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is negative (2 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Ionis Pharmaceuticals Inc?
20-day realised volatility is 37.2% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 10.7% over a month and 5.2% over a week.
What factors affect Ionis Pharmaceuticals Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Ionis Pharmaceuticals Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Ionis Pharmaceuticals Inc?
58 backtested tactical asset allocation strategies trade Ionis Pharmaceuticals Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Ionis Pharmaceuticals Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Ionis Pharmaceuticals Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Ionis Pharmaceuticals Inc historical data?
In the Free historical data section of this page: the last 10 years of Ionis Pharmaceuticals Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Ionis Pharmaceuticals Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Ionis Pharmaceuticals Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.IONS.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2026.58
2026-11-1927.22
2026-11-1827.39
2026-11-1726.96
2026-11-1628.01
2026-11-1329.06
2026-11-1227.31
2026-11-1128.33
2026-11-1028.19
2026-11-0931
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.